Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
JNJ-86974680 by Johnson & Johnson for Non-Small Cell Lung Carcinoma: Likelihood of Approval
JNJ-86974680 is under clinical development by Johnson & Johnson and currently in Phase I for Non-Small Cell Lung Carcinoma. According...